Institut Gustave Roussy, 94805 Villejuif, France.
Semin Oncol. 2013 Aug;40(4):465-71. doi: 10.1053/j.seminoncol.2013.05.002.
The sequencing of targeted therapy is well established in metastatic renal cancer. Switching between different vascular endothelial growth factor (VEGF)-targeted therapies or VEGF-targeted therapies and mammalian target of rapamycin (mTOR) inhibitors are both of proven benefit. The optimal sequence remains unclear. Unfortunately, there is a lack of biomarkers to drive decision making. In this article we review the current data and describe the treatment options for patients.
在转移性肾细胞癌中，靶向治疗的序贯治疗已经得到了很好的确立。不同的血管内皮生长因子（VEGF）靶向治疗药物或 VEGF 靶向治疗药物与哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂之间的转换均已被证实有益。最佳的序贯治疗方案仍不清楚。不幸的是，目前缺乏能够驱动决策的生物标志物。在本文中，我们回顾了当前的数据，并描述了患者的治疗选择。
